Brain-based visual prosthesis company’s new funding accelerates progress towards in-house manufacturing and first-in-human clinical trials, the first phase of which is scheduled Q3 2026.
Belgian neurotechnology company ReVision Implant has secured €4 million in an oversubscribed funding round from private investors, marking a key step in its transition from preclinical development to clinical exploration.
The oversubscribed round saw participation from both existing investors and new backers, including prominent European business leaders and experienced medtech operators, underlining strong confidence in the company’s technology and trajectory.
The funding builds on ReVision Implant’s existing support from public programmes, including multiple prestigious and hard to obtain European Innovation Council (EIC) grants such as the 2.4 M€ FlairVision project. The company is also supported by the Plug & Play and imec istart incubators.
ReVision Implant is developing a cortical visual prosthesis designed to restore functional vision in people with severe blindness, including those who cannot benefit from retinal or optic nerve-based therapies. By interfacing directly with the brain’s visual cortex, the system bypasses any damage to the eye and optic nerve, with the aim of enabling patients to perceive and interpret visual information.
The company has already begun setting up its own cleanroom facilities, which it started developing three months ago, marking a significant step towards greater control over manufacturing and quality processes as it prepares for clinical trials.
Frederik Ceyssens, CEO of ReVision Implant, said: “This funding round marks an important step as we move from development towards clinical and operational scale-up. We are investing in our own cleanroom environment to bring important manufacturing steps in-house, while expanding our team and advancing our regulatory compliance and clinical programme over the coming years.
At the same time, we are continuing product development and strengthening our collaborations with other medtech companies as we move closer to bringing our technology to patients.”
The recent advances at ReVision Implant reflects a growing momentum in high bandwidth neurotechnology. The vastly improved ability to directly interface with the brain is becoming the basis of devices that will strongly alleviate conditions such as quadriplegia, locked-in syndrome, amputations, aphasia and blindness.
Following its recent Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), the company is preparing for its first-in-human studies, of which the first phase has recently gained regulatory approval and is scheduled for Q3 2026.
Together with this latest funding, the company is now positioned to take the next critical steps towards improving the lives of millions of patients worldwide.
